Response to PEG-IFN α-2a by chronic hepatitis C patients with autoimmune features

Zhao Ping; Wang JiangBin; Jiao Jian

Issue 4

Apr. 2010

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2010 > 26(4): 374-376

PDF( 143 KB)

Response to PEG-IFN α-2a by chronic hepatitis C patients with autoimmune features

Published Date: 2010-04-20

Abstract

Abstract

Objective Study on a response to PEG-IFN α-2a in chronic hepatitis C (CHC) patients with autoimmune features and analyze the variation of serum auto antibody level before and after treatment.Methods HCV, HCV genotype, AMA, SMA, TGA and TMA were analyzed in 24 autoantibody positive and 41 autoantibody negative CHC patients before and after PEG-IFN α-2a treatment.Sandwich hybridization microplate, fluorescence quantification PCR and Indirect Immunofluorescence techniques were used.Results The response rate was higher in 65 autoantibody positive than autoantibody negative CHC patients before and after PEG-IFN α-2a treatment.The autoantibody reappeared with increased level at the end of PEG-IFN α-2a treatment, but decreased 6 months later to even lower than the pretreatment level.Response rates to PEG-IFN α-2a were significantly lower in patients with ANA and SMA compared to CHC patients without ANA and SMA.The response rate to PEG-IFN α-2a was not statistically significant between TMA and TGA.Conclusion Autoantibody positive CHC patients show lower response rate to PEG-IFN α-2a than autoantibody negative CHC patients.PEG-IFN α-2a treatment may result in the appearance and increase autoantibody level during the treatment of serious autoimmune disease, but may be recovered 6 months after the end of PEG-IFN α-2a treatment.
- autoimmunity,
- interferons,
- autoantibodies,
- hepatitis C

FullText(HTML)

References(16)

References

[1]Fried MW, Shiffman ML, Reddy KR, et al.Peginterferon alfa-2aplus ribavirin for chronic hepatitis C virus infection[J].N Engl JMed, 2002, 347 (13) ∶975-982.

[2]Cacoub P, Renou C, Rosenthal E, et al.Extrahepatic manifestationsassociated with hepatitis C virus infection:a prospective multi-cen-ter study of 321 patients[J].Medicine (Baltimore) , 2000, 79 (1) ∶47-56.

[3]Zoulim F, Chevallier M, Maynard M, et al.Clinical consequencesof hepatitis C virus infection[J].Rev Med Virol, 2003, 13 (1) ∶57-68.

[4]EL-Serag HB, Hampel H, Yeh C, et al.Extrahepatic manifesta-tions of hepatitis C among United States male veterans[J].Hepatol-ogy 2002, 36 (6) ∶1439-1445.

[5]Zhu Q, Guo JT, Seeger C.Replication of hepatitis C virus subge-nomes in nonhepatic epithelial and mouse hepatoma cells[J].Vir-ol, 2003, 77 (17) ∶9204-9210.

[6]Goutagny N, Fatmi A, De Ledinghen V, et al.Evidence of viralreplication in circulating dendritic cells during hepatitis C virus in-fection[J].J Infectious Diseases, 2003, 187 (12) ∶1951-1958.

[7]Agnello V, De Rosa FG.Extrahepatic disease manifestations ofHCV infection:Some current issues[J].Hepatol, 2004, 40 (2) ∶341-352.

[8] 中华医学会.丙型肝炎防治指南[J].中华肝脏病杂志, 2004, 9 (84) ∶194-198.

[9]Primo Vera J.Pegylated interferon-induced diabetes mellitus type1 in two patients with chronic hepatitis C[J].Gastroenterol Hepa-tol, 2004, 27 (2) ∶69.

[10]Gatselis NK, Georgiadou SP, Tassopoulos N, et al.Impact of parie-tal cell autoantibodies and non-organ-specific autoantibodies onthe treatment outcome of patients with hepatitis C virus infection:apilot study[J].World J Gastroenterol, 2005, 11 (4) ∶482-487.

[11]Kato-Motozaki Y, Komai K, Takahashi K, et al.Polyethylene gly-col interferon alpha-2b-induced immune-mediated polyradicu-loneuropathy[J].Intern Med, 2009, 48 (7) ∶569-572.

[12]Rowan AG, Fletcher JM, Ryan EJ, et al.Hepatitis C virus-specif-ic Th17 cells are suppressed by virus-induced TGF-beta[J].JImmunol, 2008, 181 (7) ∶4485-4494.

[13]ParanóR, Schinoni MI, de Freitas LA, et al Anti-Golgi complexantibodies during pegylated-interferon therapy for hepatitis C[J].Liver Int, 2006, 26 (9) ∶1148-1154.

[14]Cresta P, Musset L, Cacoub P, et al Response to interferon al-phatherapy and disappearance of cryoglobulinemia in patients infec-ted by hepatitis C virus[J].Gut, 1999, 45 (1) ∶122-128.

[15]Wasmuth HE, Stolte C, Geier A, et al.The presence of non-or-gan-specific autoantibodies is associated with a negative responseto combination therapy with interferon and ribavirin for chronic hep-atitis C[J].BMC infect Dis, 2004, 4∶4.

[16]Bayraktar y, Bayratar M, Gurakar A, et al.A comparison of theprevalence of autoantibodies in individuals with chronic hepatitis Cand those with autoimmune hepatitis:the role of interferon in thedevelopment of autoimmune diseases[J].Hepatogastroenterology, 1997, 44 (14) ∶417-425.

Relative Articles

[1]	Jing CAI, Guiqin ZHOU, Yaxing LIU, Bin LI, Xiaojing WANG, Ying FENG, Xianbo WANG. Clinical features of Polygonum multiflorum preparation-related liver injury with or without positive autoantibody[J]. Journal of Clinical Hepatology, 2022, 38(10): 2296-2301. doi: 10.3969/j.issn.1001-5256.2022.10.018
[2]	Yuanjiao GAO, Yanjie LIN, Liu YANG, Xiaoyue BI, Wen DENG, Tingting JIANG, Fangfang SUN, Yao LU, Lu ZHANG, Minghui LI, Yao XIE. Liver histopathology and clinical features of autoimmune hepatitis with different antibody statuses[J]. Journal of Clinical Hepatology, 2022, 38(12): 2744-2749. doi: 10.3969/j.issn.1001-5256.2022.12.012
[3]	Zhan WANG, Lin WANG, Yuan YAO, Jing LIU, Guirong SUN, Mingjun LIU. Value and clinical application of multiplex bead-based flow fluorescent immunoassay in the detection of autoantibodies in primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2021, 37(10): 2384-2388. doi: 10.3969/j.issn.1001-5256.2021.10.025
[4]	Dang FuTao, Tang YingMei. Diagnostic and prognostic value of autoantibodies in primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2020, 36(5): 1164-1166. doi: 10.3969/j.issn.1001-5256.2020.05.048
[5]	Zhang HaiPing, Yan HuiPing. Research advances in autoantibodies in autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 749-753. doi: 10.3969/j.issn.1001-5256.2020.04.007
[6]	Xiao Qian, Tan ShanZhong, Zhao TianHui, Sun WeiWei, Shen JianJun, Liang ZhongFeng, Jiang ShuLian. Value of anti-nuclear antibody and liver pathology in diagnosis of male patients with autoimmune liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(5): 1070-1073. doi: 10.3969/j.issn.1001-5256.2019.05.027
[7]	Xue Mei, Shen Yi, Shen MengYi, Fan XiaoLi, Men RuoTing, Yang Li. Autoimmune hepatitis-related autoantibodies and their clinical significance[J]. Journal of Clinical Hepatology, 2019, 35(6): 1392-1396. doi: 10.3969/j.issn.1001-5256.2019.06.048
[8]	Jiang HongLi, Qi YaBin, Zhang Rui, Hu YuLin. Detection rates of autoantibodies in patients with drug-induced liver injury and their clinical significance[J]. Journal of Clinical Hepatology, 2018, 34(1): 164-167. doi: 10.3969/j.issn.1001-5256.2018.01.034
[9]	Wu HuiLi, Zheng SuJun, Wang TaiLing, Yan HuiPing, Ren Feng, Li JunFeng, Chen Yu, Liu Mei, Liu Shuang, Duan ZhongPing. Pathological features of liver tissue in autoantibody-positive chronic hepatitis C patients after plasmaphoresis[J]. Journal of Clinical Hepatology, 2018, 34(2): 281-286. doi: 10.3969/j.issn.1001-5256.2018.02.013
[10]	Cao ZhangChun. Significance of combined analysis of autoantibodies in diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 178-180. doi: 10.3969/j.issn.1001-5256.2015.02.008
[11]	Nie HongMing, Chen JianJie, Wang Rong, Shen Hong. Application of interferon-free treatment regimen in treatment of chronic hepatitis C in China[J]. Journal of Clinical Hepatology, 2015, 31(5): 796-799. doi: 10.3969/j.issn.1001-5256.2015.05.041
[12]	Huang ChunYang, Liu YanMin, Huang YunLi, Han Ying, Zhang XiaoDan, Liao HuiYu. Drug-induced liver injury accompanied by autoimmune phenomena: an analysis of clinical characteristics[J]. Journal of Clinical Hepatology, 2015, 31(8): 1303-1306. doi: 10.3969/j.issn.1001-5256.2015.08.029
[13]	Liu YanMin. The clinical feature and prognosis in patients with drug induced liver injury complicated with positive autoantibodies detection[J]. Journal of Clinical Hepatology, 2012, 28(5): 335-338+342.
[14]	Yan HuiPing. Detection of autoantibodies and standardization of result report[J]. Journal of Clinical Hepatology, 2011, 27(6): 595-597.
[15]	Wang ChunYan, Hu DongSheng, Lu Wei. Detection and clinical significance of autoantibodies in patients with chronic hepatitis C in Tianjin[J]. Journal of Clinical Hepatology, 2011, 27(1): 93-95.
[16]	Wang JiaSen, Yao DingKang. Value of autoantibodies in predicting autoimmune liver disease[J]. Journal of Clinical Hepatology, 2011, 27(3): 333-336.
[17]	Zhang YanChao, Chen Ming, Chen Dan. Clinical significance of antibody profiling in autoimmune liver disease [J]. Journal of Clinical Hepatology, 2010, 26(3): 319-320.
[18]	Wang JingQuan, Cui ShiChang, Yan HuiPing, Dong ShengShan, Li DongCeng, Zhu RenPing. The clinical observation of autoantibody in autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2004, 20(1): 12-13.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (244) PDF downloads(103)

Response to PEG-IFN α-2a by chronic hepatitis C patients with autoimmune features

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Response to PEG-IFN α-2a by chronic hepatitis C patients with autoimmune features

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content